NasdaqGS:QUREBiotechs
uniQure (QURE) Is Down 62.4% After AMT-130 Lawsuits Challenge Huntington’s Disclosure Timeline - What's Changed
uniQure N.V. has reported full-year 2025 results, with revenue of US$16.1 million versus US$27.12 million a year earlier and a net loss of US$198.97 million versus US$239.56 million, alongside rising investor scrutiny over its Huntington’s disease program.
Multiple securities class action lawsuits now allege that uniQure misrepresented aspects of its AMT-130 Huntington’s trial design and regulatory timelines, intensifying focus on how core pipeline disclosures align with future regulatory...